We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 04. 02. | 장 마감 후 (AMC) | $-0.09 | — | — | $80.24M | — | 예정 |
| FY2026 Q3 | 2025. 02. 28. | 시각 미정 | — | $-0.68 | — | — | $212.34M | 보고됨 |
| FY2026 Q2 | 2024. 11. 30. | 시각 미정 | — | $-0.58 | — | — | $140.34M |
Consensus PT $18 · 4 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 04. 07. | Canaccord Genuity | — | 의견 유지 | Buy → Buy | — | Canaccord Genuity: Buy |
| 2026. 04. 06. | Freedom Broker | — | 커버리지 개시 | — → Buy | — | Freedom Broker: Buy |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| 보고됨 |
| FY2026 Q1 | 2024. 08. 31. | 시각 미정 | — | $-0.31 | — | — | $67.49M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 2,825,499 | $36.28B | 0.06% | — | 신규 편입 |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 3,181,829 | $36.18B | 0.07% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, diagnostic and interventional guidewires, and coaxial micro-introducer kits for use in peripheral diagnostic and interventional procedures. In addition, the company provides abscession drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-access kits offer interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
Stored first · Google News · Yahoo Finance (English)
ANGO Technical Analysis & Stock Price Forecast - Intellectia AI
ANGO Technical Analysis & Stock Price Forecast Intellectia AI
ANGO Stock Price, Quote & Chart | ANGIODYNAMICS INC (NASDAQ:ANGO) - ChartMill
ANGO Stock Price, Quote & Chart | ANGIODYNAMICS INC (NASDAQ:ANGO) ChartMill
AngioDynamics announces a key advancement for its NanoKnife Irreversible Electroporation (IRE) System as it achieves Medicare coverage. - Bitget
AngioDynamics announces a key advancement for its NanoKnife Irreversible Electroporation (IRE) System as it achieves Medicare coverage. Bitget
AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect
AngioDynamics (ANGO) to Present at Goldman Sachs Global Healthca - GuruFocus
AngioDynamics (ANGO) to Present at Goldman Sachs Global Healthca GuruFocus
AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - FinancialContent
AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference FinancialContent